Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
暂无分享,去创建一个
M. Roumeliotis | S. Husain | T. Meyer | M. Sia | K. Thind | P. McGeachy | H. Quon | K. Martell | R. Khanolkar